A Pilot Study of Pacritinib Combined With a BTK Inhibitor in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Latest Information Update: 08 Nov 2024
Price :
$35 *
At a glance
- Drugs Pacritinib (Primary) ; Antineoplastics
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 08 Nov 2024 New trial record